-
Innovation Ranking
Innovation Ranking – Cogent Biosciences Inc
Cogent Biosciences Inc (Cogent Biosciences) formerly, Unum Therapeutics Inc is a clinical-stage biopharmaceutical company that develops and commercializes precision therapies for genetically defined diseases. The company's pipeline product portfolio includes CGT9486 which is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis, a serious disease caused by the unchecked proliferation of mast cells....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bezuclastinib in Gastrointestinal Stromal Tumor (GIST)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bezuclastinib in Gastrointestinal Stromal Tumor (GIST) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bezuclastinib in Gastrointestinal Stromal Tumor (GIST) Drug Details: Bezuclastinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bezuclastinib in Systemic Mastocytosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bezuclastinib in Systemic Mastocytosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bezuclastinib in Systemic Mastocytosis Drug Details: Bezuclastinib (CGT-9486) is under development for...
-
Product Insights
NewGastrointestinal Stromal Tumor (GIST) – Drugs In Development, 2024
Empower your strategies with our Gastrointestinal Stromal Tumor (GIST) – Drugs In Development, 2024 report and make more profitable business decisions. Gastrointestinal stromal tumors (GISTs) are tumors that occur in the gastrointestinal tract. GISTs belong to a group of cancers called soft tissue sarcomas. GISTs can be benign or malignant. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can be felt with the hand, nausea and vomiting, vomiting blood or having blood...
-
Product Insights
NewMesenchymal Tumor Of The Gastrointestinal Tract – Drugs In Development, 2024
Empower your strategies with our Mesenchymal Tumor Of The Gastrointestinal Tract – Drugs In Development, 2024 report and make more profitable business decisions. Mesenchymal tumors represent a heterogenous group of neoplasms that include malignant, intermediate malignancy, and benign entities. Sarcomas are extremely rare, accounting for only 1% of malignancies in adults and up to 10-15% of malignancies in the paediatric population. They are characterized by a global incidence of 30-50 cases per million person-years and show a wide anatomic distribution. Rarely,...
-
Product Insights
NewHypersecretory Conditions – Drugs In Development, 2024
Empower your strategies with our Hypersecretory Conditions – Drugs In Development, 2024 report and make more profitable business decisions. Hypersecretory Condition is a group of disorders characterized by hypersecretion of gastric acid also known as hypergastrinemia. This condition can result in peptic ulcers, GERD, gastrointestinal hemorrhage causing a predominant mortality and morbidity. Underlying diseases, helicobacter pylori infection, gastric outlet obstruction, chronic renal failure and idiopathic causes results to hypersecretion of gastric juice. Diagnosed by the gastrin levels and gastric acid secretion...
-
Product Insights
NewSystemic Mastocytosis – Drugs In Development, 2024
Empower your strategies with our Systemic Mastocytosis – Drugs In Development, 2024 report and make more profitable business decisions. Systemic mastocytosis is a disorder where mast cells are abnormally increased in multiple organs including the bone marrow. Symptoms include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing, and musculoskeletal pain. Treatment includes antihistamines and more aggressive forms of medication, including interferon or chemotherapeutic agents. The Systemic Mastocytosis drugs in development market research report provide comprehensive information...
-
Product Insights
NewMast Cell Leukemia – Drugs In Development, 2024
Empower your strategies with our Mast Cell Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. Mast cell leukemia (MCL) is a rare and aggressive type of blood cell cancer. It is a subtype of systemic mastocytosis (SM) and caused by the abnormal growth of cells from myeloid progenitor cells. Symptoms include lethargy and weakness, fainting, flushing, fever, tachycardia, losing more than 10 percent of body weight, diarrhea, nausea, and vomiting. MCL diagnosis requires fulfillment of diagnostic...
-
Product Insights
NewMesenchymal Tumor – Drugs In Development, 2024
Empower your strategies with our Mesenchymal Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Mesenchymal tumors are tumors developing from mesenchymal tissues. These tissues are made of cells including fibroblasts, nerve cells, blood vessel cells, muscle cells, and others. Benign soft tissue tumors are common in humans, but cancerous mesenchymal tumors are rare. Many tumors can originate from various cells, and the treatment mainly depends on the tumor's type, severity, and aggressiveness. These are soft tissue...
-
Product Insights
NewNet Present Value Model: Cogent Biosciences Inc’s Bezuclastinib
Empower your strategies with our Net Present Value Model: Cogent Biosciences Inc's Bezuclastinib report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.